Introducing OdysseaBio
Your partner in navigating the path of innovative therapies.
We specialize in transforming preclinical and clinical data into compelling narratives that highlight your asset, resonate with stakeholders, and drive success.
The Challenge
Launching a biotech venture or bringing a new therapy to market is a monumental feat. Yet, even groundbreaking science can get lost in translation.
Ultimately, investors, healthcare providers, and patients all share the same goal—to identify and embrace innovations that improve human health.
Many biotech and life sciences companies struggle to articulate their vision, distill complex data into compelling narratives, and effectively communicate their value to the right stakeholders.
That’s where we come in.
Our Approach
We empower biotech startups, pharmaceutical companies, and patient advocacy groups to own their narrative and achieve their goals.
We don’t just develop content—we craft narratives that shape perception, influence decisions, and drive meaningful engagement.
Whether you’re securing funding, developing a strategic communications plan, or enhancing patient engagement, we provide the strategic guidance and tailored solutions to help you succeed.
The Leaders Behind OdysseaBio
As a women-owned business, we bring a fresh perspective to the industry, championing innovation that has the power to transform lives.
We’re two doctoral-level scientists turned strategic communicators, driven by a passion for transforming scientific data into impactful narratives.
-
Co-Founder
With more than a decade of experience in medical communications and a PhD in Neurology & Neurosurgery, Deborah brings a wealth of expertise across hematology, oncology, neurology/neuro-oncology, and rare diseases. She specializes in innovative therapies, including gene and cellular therapies, targeted treatments, and therapies for solid tumors.
Deborah’s research background in glioblastoma provides her with unique insights into the critical transition from preclinical to clinical stages. She has extensive experience working on medical affairs-related projects, ensuring comprehensive and accessible medical information that enhances decision-making in clinical practice. By applying a strategic approach to communication, Deborah has played a key role in the development of scientific education initiatives designed to engage and inform diverse audiences.
-
Co-Founder
Georghia holds a PhD in Pharmacology & Physiology from the UK and began her career conducting research at the Montreal Heart Institute as a Heart & Stroke Foundation of Canada postdoctoral fellow. In 2011, she transitioned into medical communications, where she’s been using her scientific expertise to make complex concepts more accessible.
Georghia has developed value messaging, led successful health technology assessment submissions, and created strategic content for a variety of audiences. Her focus areas include cardiology, hematology, oncology, and rare diseases, where she excels at transforming complex data into clear, impactful narratives. Her ability to bridge science and strategy ensures her work resonates with stakeholders and drives decision-making.
How We Help You Succeed
The journey of drug development is much like Homer’s Odyssey—long, complex, and filled with challenges. Each asset and drug development path is unique, requiring strategy, perseverance, and a clear vision to achieve lasting success.
At OdysseaBio, we understand the complexities of this journey. As an extension of your team, we provide strategic insight and expertise through every phase of development. From early discovery to late-stage trials, we help ensure your narrative evolves thoughtfully and remains aligned with your mission.
Together, we’ll craft a strategy that not only supports your immediate goals but also secures the long-term success of your product, ensuring your story endures and reaches the right stakeholders with clarity and impact.
Our Services
-
Positioning Your Company for Growth
We help you communicate your science, vision, and value proposition in a way that resonates with investors and potential partners.Investor & Business Decks – Crafting compelling presentations that highlight your asset’s potential, from seed to Series C.
FDA Reports for Investors – Translating regulatory and clinical data into clear, investor-friendly insights that support funding and business decisions.
Competitive Landscape Analyses – Providing strategic intelligence to position your company effectively.
-
Ensuring Scientific Integrity & Strategic Messaging
We bridge the gap between complex science and strategic storytelling, ensuring that your medical and scientific communications are both technically sound and impactful.Scientific & Medical Affairs Communications – Strategic messaging for advisory board decks, scientific presentations, and publications.
Horizon Scans & Data Summaries – Distilling key findings to inform decision-making.
Conference & Pre-Conference Materials – Engaging scientific communities through abstracts, posters, and presentation content.
-
Building Trust & Enhancing Patient Engagement
We ensure that patients and advocacy groups receive clear, accessible information that empowers decision-making and supports engagement.Patient-Facing Materials – Developing health literacy content, patient toolkits, and educational resources.
Patient Result Dissemination Strategies – Crafting lay-friendly summaries of clinical study results.
Multi-Stakeholder Communication Plans – Aligning messaging across industry, regulatory, and patient audiences to foster collaboration.
Our Focus
At OdysseaBio, we specialize in supporting cutting-edge therapies and innovative technologies across the entire drug development journey. With expertise spanning hematology, oncology, neurology/neuro-oncology, we’re committed to advancing the development of treatments for rare diseases, alongside a dedication to improving women’s health.
-
CAR-T and T-cell receptor therapies
NK cell therapies
Gene therapy—viral and nonviral vectors
Gene editing (CRISPR/Cas9)
-
RNA-based therapies
Bispecific antibodies
Antibody-drug conjugates
Oncolytic virus therapies
Cancer vaccines
Exosome-based therapies
-
Hematologic malignancies
Rare hematologic conditions (eg, hemophilia, sickle cell disease, beta-thalassemia)
CNS tumors and neuro-oncology
Rare cancers and rare neurologic disorders
-
Improving the health and well-being of people with rare diseases by communicating advances in care and treatment.
-
Supporting innovative therapies and technologies that enhance early detection, treatment, and care for conditions affecting women, with the goal of improving patient outcomes and quality of life.